LONDON, UK / ACCESSWIRE / October 6, 2021 / Prima, a potentially breakthrough wireless bionic vision system (BVS) that generates electrical impulses at the retinal level, continues to advance through the PRIMAvera pivotal EU study. Prima aims to restore a form of central visual perception in patients with advanced dry age-related macular degeneration (dry-AMD) involving geographic atrophy (GA). While we have pushed back our potential launch forecast to H124 (from H223), after tweaking our market growth assumptions, we now obtain a higher equity valuation of €143.3m (versus €138.0m previously).
Pixium had €10.13m in cash and €9.48m debt at 30 June, and subsequently raised €7.376m (net) in equity through a capital increase and also converted c €1.1m of debt to equity. After adding €9.1m H121 pro forma net cash, we obtain an equity valuation of €143.3m (from €138.0m, previously), largely due to slight increases in our longer-term growth assumptions, or €2.47 per basic share (from €2.41 previously). We believe that Pixium's current funds on hand should last to end Q422, and assume it will need to raise €29.4m (from €25.4m, previously), modelled as illustrative long-term debt, to bring Prima to commercial launch.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Pooya Hemami +1 646 653 7026 healthcare@edisongroup.com
Maxim Jacobs +1 646 653 7027 healthcare@edisongroup.com
Learn more atwww.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/666844/Pixium-Vision-ALPIX-Advancing-Towards-Sight-Restoration-in-Dry-AMD
